Introduction {#Sec1}
============

Head and neck squamous cell carcinoma (HNSCC) represents the sixth most common form of cancer that is diagnosed worldwide. It is the most common malignant neoplasm that arises from the mucosa of the upper aerodigestive tract (Grandis et al. [@CR12]; Hunter et al. [@CR15]). During the past 30 years, survival rates have not improved significantly for this type of cancer, and 50% of HNSCC patients still eventually die of their disease and 5% develop additional primary tumours each year (Grandis et al. [@CR12]; Hunter et al. [@CR15]). Furthermore, HNSCC has a large impact on the quality of life of all HNSCC patients and survivors (Bernier et al. [@CR5]; Cooper et al. [@CR7]). Significant morbidity caused by the treatments often mandates long-term multidisciplinary care, which leads to increased financial burdens for institutions that treat HNSCC patients (Hunter et al. [@CR15]). The management of head and neck cancer has become increasingly complex in recent years due to combined-modality treatment regimens as well as the integration of new diagnostic and therapeutic technologies. Nearly two-thirds of HNSCC patients present with advanced disease (stages III and IV). Despite the use of resection and concomitant post-operative chemotherapy and radiotherapy, these advanced HNSCCs frequently recur in the original tumour beds (Hunter et al. [@CR15]; Schantz et al. [@CR27]). Patients with stage IV hypopharyngeal carcinoma represent one of the HNSCC subgroups with the worst prognosis, as the 5-year survival rate for this population is less than 15%.

Biological markers are therefore required to identify the high-risk HNSCC patients who are in need of highly aggressive treatments after surgical resection of their tumours (Grandis et al. [@CR12]). Over the last 10 years, it has become clear that there is a subset of oropharyngeal squamous cell carcinomas (OSCCs) that is associated with high-risk human papillomavirus (hrHPV) infection, in particular HPV type 16 (D'Souza et al. [@CR8]). HPV-positive OSCCs seem to be different from HPV-negative tumours with respect to tumour differentiation, risk factors and the genetic changes that are present, indicating that HPV-positive OSCCs represent a separate tumour entity from HPV-negative OSCCs, which have specific molecular pathways associated with their tumourigenicity (Reimers et al. [@CR23]). A recent case--control study comparing 100 patients with OSCC and 200 control patients demonstrated that oral HPV infection was strongly associated with oropharyngeal carcinoma among patients who did not have the classical risk factors of tobacco and alcohol use (D'Souza et al. [@CR8]). This study also demonstrated that a high lifetime number of oral sex or vaginal sex partners, engagement in casual sex, early age at first intercourse and infrequent use of condoms were all associated with HPV-16-positive oropharyngeal cancer (D'Souza et al. [@CR8]).

Molecular studies of cervical carcinoma, the cancer that has the most widely accepted association with HPV, have shown that after integration of the virus, the expression of the transcription factor E2 (which represses the transcription of E6 and E7 oncogenes) is disrupted. As a consequence of this disruption, the E6 and E7 genes are transcribe and result in the production of oncoproteins that bind to and degrade the p53 and retinoblastoma (Rb) tumour suppressor, respectively. The p16 protein functions as a tumour suppressor by binding to the cyclin D1 CDK4/CDK6 complex, thereby preventing phosphorylation of the Rb protein. Rb downregulation subsequently results in p16 upregulation (Weinberger et al. [@CR30]). Begum et al. ([@CR4]) have shown that p16 overexpression is a marker of oropharyngeal origin and has association with HPV infection in HNSCC tumours. In contrast, in tobacco-related HNSCCs, the loss of the tumour-suppressor p16 protein is a common and early event in tumourigenesis (Reed et al. [@CR22]). Several studies that were dedicated to studying oral and oropharyngeal carcinomas have demonstrated that HPV-positive patients have a better prognosis than HPV-negative patients (Ritchie et al. [@CR24]; Weinberger et al. [@CR30]). A more recent study showed that HPV-16 copy number was positively associated with response to concomitant chemoradiotherapy and with better overall and disease-specific survival (Kumar et al. [@CR17]). Moreover, joint assessment of p53 expression and HPV infection seems to provide an excellent indicator of prognosis (Smith et al. [@CR29]). In a large series of 294 HNSCCs with 10 years of follow-up, Smith et al. ([@CR29]) observed that patients with tumours that were p53−/hrHPV+ had the highest survival and lowest recurrence rates, whereas patients with tumours that were p53+/HPV− had significantly worse outcomes.

Despite their promise as prognostic markers for patients with OSCC, no studies have been performed to analyse the prognostic implication of this combination of markers in patients with hypopharyngeal carcinoma. In the current study, we examined the clinical utility of the combination of the most promising predictive markers for OSCC, including HPV DNA detection as well as p16, p21 and p53 expression in a homogeneous series of 75 patients with stage IV hypopharyngeal SCC.

Materials and methods {#Sec2}
=====================

Histopathological and clinical data {#Sec3}
-----------------------------------

Formalin-fixed, paraffin-embedded hypopharyngeal squamous cell carcinoma (HSCC) tumour specimens were obtained from 4 female and 71 male patients who underwent radical curative-intent surgery between January 1996 and December 2000 in the E.N.T. Department of the *Hôpital Claude Huriez* (Lille, France). For each surgical specimens, we have selected the paraffin block presenting the higher proportion of carcinoma (avoiding necrotic area frequently observed in the central part of the tumour). Clinical staging was performed according to the TNM classification system (Wittekind et al. [@CR31]), and data regarding the tumours of the 75 stage IV hypopharyngeal patients included in this study are detailed in Table [1](#Tab1){ref-type="table"}. The diagnoses were established based on the histological criteria previously described by Hyams et al. ([@CR16]). All hypopharyngeal SCCs included in this study were primary tumours, and the patients did not have distant metastases or recurrences. The tumours were categorised as well-differentiated (*n* = 38), moderately differentiated (*n* = 26) and poorly differentiated (*n* = 11). This retrospective study was approved by the local Institutional Review Board.Table 1Patient characteristicsMean age: 55 years (range 40--78)Gender Male: 71 patients (95%) Female: 4 patients (5%)Localisation Piriform sinus: 56 cases (75%) Postcricoid area: 16 cases (21%) Posterior wall: 3 cases (4%)Grade Well differentiated: 38 cases (51%) Moderately differentiated: 26 cases (34%) Poorly differentiated: 11 cases (15%)TNM stage: (*n* = 75 cases of stage IV disease) T2N2: 8 cases T3N2: 7 cases T4N0: 12 cases T4N1: 6 cases T4N2: 39 cases T4N3: 3 casesTreatment Partial pharyngolaryngectomy: 9 cases Total pharyngolaryngectomy: 49 cases Circular pharyngolaryngectomy: 8 cases Esopharyngolaryngectomy: 9 cases 28 presented larynx cartilage invasion 112 neck dissections in 75 patients 47 patients with extranodal spread All patients were treated with standard post-operative radiotherapy, but did not receive post-operative chemotherapy.Recurrence: (*n* = 23) Local recurrence: 17 cases Distant recurrence: 11 casesFollow-up: (72 patients had clinical follow-up data available) 9 second primary cancers: 6 cases of lung cancer, 1 case of prostate cancer, 1 case of kidney cancer 6 head and neck second primaries 29 deaths, including 20 caused by the HNSCC and 9 deaths that were unrelated to HNSCC (5 caused by a second primary cancer, 3 caused by medical disease, and 1 from unknown causes)

All of the hypopharyngeal SCC specimens used in this study came from patients who did not undergo chemotherapy and/or radiotherapy before surgery. After surgery, all patients were treated with standard post-operative radiotherapy, but not chemotherapy. All patients used alcohol and tobacco. Thus, the 75 stage IV hypopharyngeal SCC specimens that were included in this study comprised a very homogeneous sample, both clinically and histopathologically.

DNA extraction {#Sec4}
--------------

The formalin-fixed, paraffin-embedded tissue samples were sectioned (10 × 5 μm), deparaffinised and digested with proteinase K by overnight incubation at 56°C. DNA was purified using the QIAamp DNA Mini Kit (Qiagen, Benelux, Belgium) according to the protocol recommended by the manufacturer.

Detection of HPV by polymerase chain reaction (PCR) amplification {#Sec5}
-----------------------------------------------------------------

HPV detection was performed by PCR using GP5+/GP6+ primers (synthesised by Eurogentec, Liege, Belgium). These GP5+/GP6+ primers amplify a consensus region located within L1 region of the HPV genome. PCR for HPV-L1 DNA amplification was performed in 25 μl of a reaction mixture containing 2 μl of extracted DNA, 2.5 μl 1 × PCR buffer, 0.025 U Taq DNA polymerase (Roche, Mannheim, Germany), 200 μM dNTPs and 0.5 pmol of each primer. The cycling conditions for PCR were as follows: denaturation was performed at 94°C for 1 min, annealing was performed at 40°C for 1 min 30 s and extension was performed at 72°C for 2 min for a total of 40 amplification cycles. The first cycle was preceded by a 3-min denaturation step at 94°C. The last cycle was followed by an additional 5-min extension step at 72°C. Aliquots (10 μl) of each PCR product were electrophoresed through a 1.8% agarose gel and stained with ethidium bromide to allow for visualisation of the amplified HPV-L1 DNA fragments.

Real-time quantitative PCR amplification of type-specific HPV DNA {#Sec6}
-----------------------------------------------------------------

All DNA extracts were tested for the presence of 18 different HPV genotypes using TaqMan-based real-time quantitative PCR targeting type-specific sequences of the following viral genes: 6 E6, 11 E6, 16 E7, 18 E7, 31 E6, 33 E6, 35 E6, 39 E7, 45 E7, 51 E6, 52 E7, 53 E6, 56 E7, 58 E6, 59 E7, 66 E6, 67 L1 and 68 E7 (Depuydt et al. [@CR10]). For the different real-time quantitative PCR assays, the analytical sensitivity ranged from 1 to 100 copies and was calculated using standard curves for 18 type-specific PCRs constructed with plasmids containing the entire genome of the different HPV types (Depuydt et al. [@CR11]). Real-time quantitative PCR for the detection of β-globin was performed in each PCR assay to verify the quality of the DNA in the samples and to measure the amount of input DNA (Arbyn et al. [@CR3]; Depuydt et al. [@CR11]).

The following HPV types that were tested were considered to be high-risk (hr): 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59 and 66.

Immunohistochemistry {#Sec7}
--------------------

All tumour samples were fixed in 10% buffered formaldehyde for 24 h, dehydrated and embedded in paraffin. Immunohistochemistry was performed on 5-μm-thick sections mounted on silane-coated glass slides (Saussez et al. [@CR26]). Before starting the immunohistochemistry protocol, deparaffinised tissue sections were placed in a 0.01 M citrate buffer (pH 6.0) and briefly pre-treated in a microwave for 2 × 5 min at 900 W. The sections were then incubated with a solution of 0.4% hydrogen peroxide for 5 min to block endogenous peroxidase activity, rinsed in phosphate-buffered saline (PBS; 0.04 M Na~2~HPO~4~, 0.01 M KH~2~PO~4~ and 0.12 M NaCl, pH 7.4) and successively exposed to solutions containing avidin (0.1 mg/ml in PBS) and biotin (0.1 mg/ml in PBS) for 20-min periods to avoid false-positive staining reactions resulting from the presence of endogenous biotin. After a thorough washing with PBS, the sections were incubated for 20 min with a solution of 0.5% casein in PBS and sequentially exposed to the following solutions: (1) the specific primary antibody; (2) the corresponding biotinylated secondary antibody (polyclonal goat anti-rabbit IgG); (3) the avidin--biotin-peroxidase complex (ABC kit), all at room temperature. The samples were subjected to thorough washing steps to remove unbound proteins in between incubation steps. The antigen-dependent presence of the peroxidase complex in the sections was visualised by incubation with the chromogenic substrates containing diaminobenzidine and H~2~O~2~. After rinsing, the sections were counterstained with luxol fast blue and mounted in a synthetic medium. To exclude antigen-independent staining, the incubation step with primary/secondary antibodies was omitted from the protocol in control samples. In all instances, these controls were negative. The biotinylated secondary antibodies and ABC kit were obtained from DakoCytomation (Glostrup, Denmark). The p16, p21 and p53 antibodies came, respectively, from Abcam (for p16 and p21, Cambridge, UK) and DakoCytomation (Glostrup, Denmark). Assessment of p16, p21 and p53 immunoreactivities was performed by two investigators who were blinded to the clinical details of the patients. Tumours were classified in a binary manner as either p16-, p21- and p53-positive (strong, diffuse staining) or p16-, p21- and p53-negative (weak or absent staining; i.e., the labelling index (LI) corresponding to the percentage of immunopositive cells was ≤5%).

Data analysis {#Sec8}
-------------

Categorical data from independent groups were compared using the chi-square test or Fisher's exact test as appropriate. Survival was measured in months from the date of diagnosis until death or until the date at which patient was last known to be alive. The standard survival time analyses were performed using Kaplan--Meier curves and the Gehan generalised Wilcoxon and log-rank tests. The statistical analyses were performed using the Statistica software package (Statsoft, Tulsa, USA).

Results {#Sec9}
=======

HPV status as determined by the GP5+/GP6+ consensus primer and by real-time quantitative PCR amplification of type-specific HPV DNA and correlation with clinicopathological parameters {#Sec10}
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A total of eight cases of the 75 specimens were found to have insufficient tissue quantities available for DNA extraction or quantitative PCR after pathological evaluation and immunohistochemistry and were therefore excluded from further analysis (Fig. [1](#Fig1){ref-type="fig"}). Out of the remaining 67 cases, another six cases, which were β-globin PCR-negative, were also excluded from further analysis. Ultimately, 61 β-globin PCR-positive specimens were typed using quantitative real-time PCR using primers for 18 different HPV types (Fig. [1](#Fig1){ref-type="fig"}). From this homogenous group of 61 HSCC tumour specimens, we identified 50 patients (82%) whose tumours tested positive for the following hrHPV types: HPV 16 (37 cases), 18 (4 cases), 33 (11 cases), 39 (1 case), 51 (5 cases), 53 (1 case), 58 (2 cases), 59 (1 case) and 66 (4 cases). Twelve patients were infected with multiple types of hrHPV. In the hrHPV− negative subgroup (*n* = 11), four patients tested positive for HPV infection using the GP5+/GP6+ consensus primers and were considered to be infected with low-risk (lr) HPV types (Fig. [1](#Fig1){ref-type="fig"}). Only seven tumours were negative for both GP5+/GP6+ and type-specific HPV PCR analysis (11%). Among the 50 patients with hrHPV+ tumours, 38 tumours were both GP5+/GP6+-positive and type-specific HPV-positive (hrHPV+ group). However, 12 tumours were GP5+/GP6+-negative and type-specific HPV-positive, corresponding to an integrated HPV+ group (int. hrHPV+) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of the processing and HPV PCR results from formalin-fixed, paraffin-embedded hypopharyngeal carcinoma specimens included in this study. Archived tissue blocks were obtained from 75 patients who underwent curative-intent surgery for stage IV hypopharyngeal carcinoma between January 1996 and December 2000. Eight samples could not be analysed due to insufficient material, and in another six samples, β-globin could not be amplified. Therefore, 61 cases were analysed by type-specific real-time PCR. Among these patients, 82% tested positive for infection with one or several types of hrHPVs, 7% were positive for lrHPV and 11% were HPV−. Among the 50 patients with hrHPV+ tumours, 38 tumours were both GP5+/GP6+-positive and type-specific HPV-positive (hrHPV+ group). However, 12 tumours were GP5+/GP6+-negative and type-specific HPV-positive, corresponding to an integrated HPV+ group (int. hrHPV+)

The mean age and the sex ratio of the patients with hrHPV+ tumours (50 cases) were both identical to those of the patients with HPV- or lrHPV+ tumours (11 cases). Statistical analysis did not reveal a significant correlation between hrHPV positivity (as determined by E6/E7 real-time quantitative PCR amplification), and the percentage of tumours that were poorly differentiated or had lymph node involvement, capsular effraction or laryngeal cartilage invasion (Table [2](#Tab2){ref-type="table"}). The hrHPV positivity was not found to be correlated with the proportion of disease-free patients in our series of patients with stage IV hypopharyngeal carcinoma (Fig. [2](#Fig2){ref-type="fig"}). However, 32% (16/50 cases) of patients with hrHPV+ tumours recurred, when compared to 8% of patients with HPV− or lrHPV+ tumours. The 5-year disease-free survival was 88% in HPV− or lrHPV+ tumours *versus* 58% in hrHPV+ tumours (log-rank test, NS).Table 2Correlation between HPV status and the percentage of patients with lymph node involvement, capsular effraction or cartilage infiltration as well as p16, p21 and p53 expressionhrHPV+ versus HPV− or lrHPV+:*p: NSLymph node involvement: N0Lymph node involvement: N*+hrHPV+11/50 (22%)39/50 (78%)HPV− or lrHPV+1/11 (9%)10/11 (91%)*p: NSCapsular effraction: NoCapsular effraction: yes*hrHPV+18/48 (37.5%)30/48 (62.5%)HPV− or lrHPV+4/11 (36%)7/11 (64%)*p: NSCartilage invasion: NoCartilage invasion: yes*hrHPV+32/49 (65%)17/49 (35%)HPV− or lrHPV+4/11 (36%)7/11 (64%)*p: NSp 16*+*p 16*−hrHPV+5/46 (11%)41/46 (89%)HPV− or lrHPV+0/10 (0%)10/10 (100%)*p: NSp 21*+*p 21*−hrHPV+35/44 (79.5%)9/44 (20.5%)HPV− or lrHPV+9/11 (82%)2/11 (18%)*p: NSp 53*+*p 53*−hrHPV+16/48 (33%)32/48 (67%)HPV− or lrHPV+4/11 (36%)7/11 (64%)*NS* not significantFig. 2Disease-free survival curves for high-risk HPV+ (hrHPV+) *versus* HPV− and low-risk HPV+ (lrHPV+) patients. The *P*-value is not significant (NS)

p16 expression as determined by immunohistochemistry (IHC) {#Sec11}
----------------------------------------------------------

Immunohistochemical expression of p16 was detected in 7 (9%) out of 75 tumours (Fig. [3](#Fig3){ref-type="fig"}a,b,c). As visualised in Fig. [3](#Fig3){ref-type="fig"}b, p16 displayed a diffuse cytoplasmic/nuclear pattern of expression that was dichotomous \[highly expressed (Fig. [3](#Fig3){ref-type="fig"}b) *versus* low/no expression (Fig. [3](#Fig3){ref-type="fig"}a)\]. When all tumours that expressed p16 (7 cases) were compared to those that did not (68 cases), p16 positivity was found to correlate with a better prognosis. In fact, all patients whose tumours expressed p16 were free of disease (Fig. [3](#Fig3){ref-type="fig"}c). The 5-year disease-free survival rate was 100% in p16+ tumours *versus* 58% in p16− tumours (*P* = NS). This difference was not statistically significant, probably due to the small size of the p16+ group (log-rank test: NS). All hrHPV+ patients' tumours expressed p16 (Table [2](#Tab2){ref-type="table"}).Fig. 3Typical p16 immunohistochemical staining profile for stage IV hypopharyngeal carcinomas (**a**: p16 non-expressor and **b**: p16 expressor). **c** shows the survival curves for p16-expressor *versus* p16-non-expressor patients. The *P*-value is not significant (NS). Magnification **a**--**b** ×320

p21 expression as determined by IHC {#Sec12}
-----------------------------------

Immunohistochemical expression of p21 was detected in 84% of HSCC specimens (Fig. [4](#Fig4){ref-type="fig"}). Moderate-to-intense brown nuclear staining was considered to be a positive result (Fig. [4](#Fig4){ref-type="fig"}). The 5-year disease-free survival rate was 60% in p21+ tumours *versus* 70% in p21− tumours. The proportion of disease-free patients was not significantly different between the p21+ and p21− groups (Fig. [4](#Fig4){ref-type="fig"}c). Similar rates of p21 positivity were observed in the hrHPV+ tumour group (79.5% were p21 +) and in the HPV− or lrHPV+ tumour group (82% were p21+) (Table [2](#Tab2){ref-type="table"}).Fig. 4Typical p21 immunohistochemical staining profile for stage IV hypopharyngeal carcinomas (**a**: p21 non-expressor and **b**: p21 expressor). **c** shows the survival curves for p21-expressor *versus* p16-non-expressor patients. The *P*-value is not significant (NS). Magnification **a**--**b** ×320

p53 expression as determined by IHC {#Sec13}
-----------------------------------

Due to insufficient biopsy material, two cases could not be analysed for p53 expression. Overexpression of p53 was detected in 27 of the 73 (37%) hypopharyngeal SCC samples that were analysed (Fig. [5](#Fig5){ref-type="fig"}). In the HPV− group, 36% of tumours (4/11) were found to overexpress p53, whereas 33% of tumours in the hrHPV+ group (16/48 cases) were found to overexpress p53 (Fisher's exact test, NS) (Table [2](#Tab2){ref-type="table"}). As shown in Fig. [5](#Fig5){ref-type="fig"}b, p53 expression was assessed by the presence of typical nuclear staining. Survival analysis showed that p53 overexpression was significantly associated with worse prognosis in our homogenous series of stage IV hypopharyngeal SCC patients (Fig. [5](#Fig5){ref-type="fig"}c). The 5-year disease-free survival was 73% in p53− tumours *versus* 48% in p53+ tumours (log-rank test, *P* = 0.008).Fig. 5Typical p53 immunohistochemical staining profile for stage IV hypopharyngeal carcinomas (**a**: p53 non-expressor and **b**: p53 expressor). **c** shows the survival curves of p53-expressor *versus* p53-non-expressor patients. Magnification **a**--**b** ×320

We carried out multivariate Cox regression models on clinical and biological variables (age, node status, capsular effraction, QPCR-PCR HPV, p16, p21, p53 expression). These analyses confirmed univariate results, i.e. only p53 brought significant contribution to prognosis. No other clinical or biological variable was able to significantly contribute to the model (data not shown).

Discussion {#Sec14}
==========

Epidemiological, molecular and clinical evidence indicate that hrHPV may play a pivotal role in the development of HNSCCs. However, most previous studies on this topic have focused on OSCCs (Dahlstrand et al. [@CR9]). D'Souza et al. ([@CR8]) showed that oral HPV infection was significantly associated with OSCC among patients with or without a history of tobacco and alcohol use. In a Swedish study, oral hrHPV infection was associated with dramatically increased risk of OSCC development (odds ratio 230) after adjusting for alcohol and tobacco consumption (Hansson et al. [@CR13]). Several studies have suggested that oral HPV infection is sexually acquired (D'Souza et al. [@CR8]; Hansson et al. [@CR13]). However, even though oral-genital contact may be implicated in oral HPV transmission, transmission through direct mouth to mouth contact or other means could not be excluded (Saussez et al. [@CR26]). Tonsillar crypts, which have an oropharyngeal sublocation that is histologically similar to the transformation zone of the uterine cervix, seem to be particularly susceptible to HPV-induced malignant transformation (D'Souza et al. [@CR8]; Hansson et al. [@CR13]; Psyrri and DiMaio [@CR21]). HPV-associated carcinomas tend to be poorly differentiated, and HPV-16 is the most prevalent genotype that is present in this type of tumour. Moreover, other studies have demonstrated that patients with hrHPV+ OSCC have a better prognosis than hrHPV− OSCC patients and that specific subgroups of hrHPVs+ tumours (specifically, those that have certain molecular profiles, such as p16 overexpression or p53 underexpression) were associated with better disease-free survival rates (Reimers et al. [@CR23]; Ritchie et al. [@CR24]; Smith et al. [@CR29]; Weinberger et al. [@CR30]). Several studies have also demonstrated the involvement of HPV infections in laryngeal and sino-nasal tumours (Aaltonen et al. [@CR1]; Alos et al. [@CR2]). Very few publications have focused on HPV positivity in hypopharyngeal cancers. Our results revealed that a large percentage (82%) of the tumour specimens that we studied were hrHPV+. These findings are in accordance with a previous study by Morgan et al. ([@CR18]) who described for the first time that 75% of the 16 pharyngolaryngeal carcinomas in their series were HPV+. Another study found a lower HPV positivity rate (46%) in the tumours of 78 previously untreated patients with laryngeal and hypopharyngeal carcinomas (Clayman et al. [@CR6]). The authors concluded that HPV+ tumours represented a biologically distinct subset of tumours that had a worse prognosis than HPV− tumours (Clayman et al. [@CR6]). In contrast to our results, Paz et al. ([@CR20]) did not identify any HPV+ tumours in a small series of 7 hypopharyngeal carcinoma patients. This finding might be explained by the fact that, in our study, we used a very sensitive (10--100 copies per PCR reaction) and type-specific real-time quantitative PCR analysis with a short amplification product (60--80 bp), which is less vulnerable to the presence of degraded DNA in paraffin-embedded specimens than some other analytical methods. We demonstrated for the first time in a large series of stage IV HSCC patients that 82% of tumours had hrHPV DNA present. Furthermore, a significant number of patients (20%) were infected with multiple types of hrHPV.

The significance of hrHPV infection and its relationship with patient prognosis is still an important matter of debate, especially considering the contradictory results that are present in different studies in the literature (Dahlstrand et al. [@CR9]; Rosenquist et al. [@CR25]). Several studies have demonstrated that the presence of HPV DNA in tonsillar carcinomas is a favourable prognostic factor with regard to clinical outcomes (recurrence and survival) (Dahlstrand et al. [@CR9]). In contrast, a recent study by Rosenquist et al. ([@CR25]) showed that among patients with oral and oropharyngeal tumours, the hrHPV+ subgroup had a higher risk of recurrence or development of second primary tumour, but had a lower risk of death due to intercurrent disease, when compared to the hrHPV− group. In the current study, we were not able to find a significant correlation between hrHPV positivity and clinical data (specifically, tumour differentiation, lymph node involvement, capsular effraction or laryngeal cartilage invasion). However, our hrHPV+ group had a higher recurrence rate (32%, 16/50 cases) than the HPV− and lrHPV+ groups (8%, 1/11 cases). This finding suggests that hrHPV positivity may be associated with an elevated risk of tumour recurrence.

The oncoprotein E6 targets p53 for ubiquitin-mediated degradation, while E7 binds to and inactivates the protein product of the tumour-suppressor gene Rb (Munger et al. [@CR19]; Scheffner et al. [@CR28]). The p16 tumour suppressor gene is often upregulated in HPV-induced cancers because it is negatively regulated by pRb (Hara et al. [@CR14]). In contrast, loss of p16 protein expression is a common and early event in the development of tobacco-related HNSCCs. Thus, tobacco/alcohol-associated HNSCCs appear to be associated with p16 downregulation and the TP53 gene mutation that results in the accumulation of p53 (corresponding to p53 overexpression) (Psyrri and DiMaio [@CR21]). Our results demonstrate that the biology of hypopharyngeal SCCs is probably more complex than previously thought and that their tumourigenesis could involve several different molecular pathways. Our results illustrate the typical tobacco-related loss of p16 expression; only 11% of the tumours in our case series, which were obtained from patients who used tobacco and alcohol, expressed this protein. Thus, p16 overexpression seems to be associated with an improved prognosis. We did not find a statistical difference between the survival curves of p16+ expressors and non-expressors (seven p16-expressor patients did not suffer recurrence). The results of our study show that hrHPV tumours have higher recurrence rates if these tumours also overexpress p53 (when compared to p53−/HPV− tumours) (Table [2](#Tab2){ref-type="table"}). Therefore, our findings suggest that p53 status plays a more significant role in predicting recurrence than hrHPV status. This finding was also recently described by Smith et al. ([@CR29]) in a large series of 294 HNSCC patients.

The strengths of our study include that we had a relatively large, very homogenous case series comprised of patients with stage IV hypopharyngeal carcinoma with similar tobacco and alcohol habits. We were also able to study the both independent and combined effects of p16, p21, p53 and HPV status with regard to clinical outcomes (recurrence and survival). Another strength of this study was that we had very good follow-up; we had recurrence and survival data with a significant follow-up period available for 96% of our patients. Finally, we emphasise that our hypopharyngeal carcinoma series is composed of only resectable stage IV (60/75 cases presented negative surgical margins) hypopharyngeal carcinomas. This finding likely explains the relatively good overall survival rates for stage IV hypopharyngeal carcinoma that we observed among this patient group.
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